Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis

National Institutes of Health (NIH)

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: Myopathy; Cystinosis

Treatments: Drug: rh Growth Hormone

Study type: Interventional

Funder types: NIH

Identifiers

NCT02124070

14-HG-0101

140101

Details and patient eligibility

About

Background:

-(Degree)ystinosis is an inherited disease. If not treated correctly, it can cause muscle wasting and weakness and kidney damage. Researchers want to learn if growth hormone (GH) can help people with cystinosis.

Objective:

• To learn if GH treatment can slow or reverse muscle wasting and improve muscle strength in people with cystinosis.

Eligibility:

• People 18 and older who are already enrolled in protocol 78-HG-0093.

Design:

• Participants will be admitted to the clinic for eight 3 4 day visits, mostly four months apart.
• At each visit, participants will have a history and physical exam and give urine and blood samples.
• At month 0 or 13, participants will take tests that will be repeated at their 12- or 25-month visit:
• They will have an eye exam, medical consultations, and strength and movement tests.
• They will complete questionnaires.
• They may have tests of heart activity and lung function.
• They will have ultrasound imaging of their arm and hand muscles. They will have a scan of their legs while lying in a magnetic resonance imaging machine (a big metal cylinder). They will have a DEXA bone scan (two X-ray beams measure body composition). They will also swallow barium while X-ray imaging records the throat muscles.
• Participants will be randomly assigned to either receive or not receive GH for the first 12 months. Then, at month 13, if they received GH, they will switch for the next 12 months.
• Participants will take GH as a daily injection. They will be taught how to give the injections.

Full description

Cystinosis is an autosomal recessive storage disorder due to defective transport of the amino acid cystine out of cellular lysosomes. Cystine accumulation leads to cellular dysfunction in most of organs and tissues. Available treatment with the cystine-depleting agent, cysteamine, can prevent or delay organ damage, including that of muscles. In poorly treated patients, however, a progressive vacuolar myopathy with muscle wasting beginning in the second decade of life significantly debilitates some patients. Muscle biopsy demonstrates prominent unrimmed vacuoles with small ring fibers but no evidence of endomysial inflammation. Plasma and muscle carnitine deficiency, impairing mitochondrial fatty acid metabolism, might also limit muscle energy production. Growth Hormone (GH) can potentially counter the muscle wasting of cystinosis patients. It has consistently induced anabolic effects in patients in malnourished or catabolic states, by enhancing the growth and development of bone, connective tissue, viscera, fat, and musculoskeletal muscles. GH, at doses of approximately 0.006 to 0.1 mg/kg/day, has proven safe and effective in HIV/AIDS wasting, parenteral nutrition-dependent short bowel syndrome, pediatric chronic kidney disease, and adult and pediatric GH-deficiency states. The current protocol is a randomized (to treatment or no treatment) crossover clinical trial to determine if GH (0.03 mg/kg/day) is beneficial for muscle wasting in cystinosis. Patients are examined at the NIH Clinical Research Center every 4 months for 2 years. Change in muscle mass will serve as the primary outcome parameter, and rhGH (Humatrope) will be provided by Eli Lilly. HumatropeR (somatropin) is currently approved by the FDA for:

• Treatment of children with short stature or growth failure associated with growth hormone (GH) deficiency, Turner syndrome, idiopathic short stature, SHOX deficiency, and failure to catch up in height after small for gestational age birth.
• Treatment of adults with either childhood-onset or adult-onset GH deficiency.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• INCLUSION CRITERIA:
• Age 18-70 years, either gender
• Diagnosis of nephropathic cystinosis confirmed by leucocyte cystine levels
• Evidence of muscle involvement such as decrease of muscle mass, weakness or EMG findings and/or documented abnormal swallowing study and PFT results
• Ability to travel to the NIH Clinical Research Center for admissions
• Ability to consent
• Compliant with cysteamine treatment regimen
• Availability of local medical follow-up

ENCLUSION CRITERIA:

• Not able to self administer daily subcutaneous injections, or not able to identify a family member/caregiver to administer them to you.
• Age <18
• Psychiatric illness or neurological disease that interferes with compliance or communication with health care personnel
• Current malignancy or history of malignancy
• Uncontrolled hypertension (blood pressure >180 systolic or >95 diastolic)
• Poor controlled hyperglycemia (fasting blood glucose level >160)
• Serum creatinine level >1.8 mg/dL
• Pregnancy

Children are excluded because the critical issues of dosage and safety can be answered in adults, and because children with cystinosis are rarely affected with the symptoms of myopathy. Patients with chronic renal failure, treated with hemodialysis will not be excluded from the study, as GH is not contraindicated for such patients. Patients received renal transplants are not excluded from the study as GH treatment are not a contraindication for such patients. Enrolled patients must be able to travel to the NIH in case adverse events occur locally after discharge from the NIH Clinical Research Center. Other medical exclusions will help to avoid the spurious assignation of side effects to rhGH.